Pharmacyclics plans to issue a material update on the ibrutinib clinical development program and its results in a press release after the EHA oral presentations. Oral Presentation at EHA, Amsterdam, The Netherlands (June 14-17, 2012) Date/Time: Saturday, June 16, 2012; 8:00 AM – 8:15 AM CET Location: Elicium 1 Abstract # 1970: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Relapsed or Refractory and Treatment Naive Chronic Lymphocytic Leukemia Patients, Updated Results of a Phase Ib/II Study. Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas. Oral Presentation at EHA, Amsterdam, The Netherlands (June 14-17, 2012) Date/Time: Saturday, June 16, 2012; 8:15 AM – 8:30 AM CET Location: Elicium 1 Abstract # 1590: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study. Dr. Jennifer Brown et al. Dana-Farber Cancer Institute, Boston, Massachusetts.